Your AI-Trained Oncology Knowledge Connection!

Zev A. Wainberg, MD

home / authors / zev-a-wainberg-md

Articles

Starting at the Front Line in Metastatic Pancreatic Cancer As New Options Emerge, How Do You Select and Sequence?

Zev A. Wainberg, MD;Tanios S. Bekaii-Saab, MD, FACP;Eileen M. O'Reilly, MD;Shubham Pant, MD, MBBS

October 1st 2024

Experts in gastrointestinal cancer focus on frontline therapy options for patients with pancreatic cancer.

An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.

NALIRIFOX Worth Consideration in Pancreatic Ductal Adenocarcinoma, Says Expert

Zev A. Wainberg, MD

February 21st 2023

An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.

Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.

NALIRIFOX Demonstrates Consistent Safety in Metastatic Pancreatic Cancer

Zev A. Wainberg, MD

February 19th 2023

Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.

An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.

NAPOLI-3 Study Answers ‘Important Question’ in Metastatic Pancreatic Cancer

Zev A. Wainberg, MD

February 15th 2023

An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.

Zev A. Wainberg, MD, on Future Research Efforts for Patients With Advanced Gastric Cancer

Zev A. Wainberg, MD

February 7th 2022

Zev A. Wainberg, MD, discusses future research efforts for the treatment of patients with advanced gastric cancer.

Zev A. Wainberg, MD, Highlights the Rationale for Examining Long-Term Data From Pembrolizumab/Chemo in Advanced Gastric/GEJ Adenocarcinoma

Zev A. Wainberg, MD

January 29th 2022

Zev A. Wainberg, MD, spoke to the rationale for examining the efficacy of pembrolizumab alone and in combination with chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma.

In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology Gastrointestinal Cancer Symposium, Zev A. Wainberg, MD, discussed key updates from the phase 3 KEYNOTE-062 trial, examining pembrolizumab plus or minus chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma.

Zev A. Wainberg, MD, on Findings From the Updated KEYNOTE-062 Trial With Pembrolizumab/Chemo for Advanced Gastric/GEJ Adenocarcinoma

Zev A. Wainberg, MD

January 21st 2022

In an interview with CancerNetwork® during the 2022 Gastrointestinal Cancer Symposium, Zev A. Wainberg, MD, discussed key updates from the phase 3 KEYNOTE-062 trial, examining pembrolizumab plus or minus chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma.